Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma

Danish Medical Bulletin

Volumn 54, Issue 4, 2007, Pages 249-265

  Donskov, Frede ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BETA INTERFERON; BEVACIZUMAB; CD57 ANTIGEN; ERLOTINIB; GAMMA INTERFERON; HISTAMINE; HLA ANTIGEN CLASS 1; HLA E ANTIGEN; HLA G ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; ISOTRETINOIN; LACTATE DEHYDROGENASE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY I 131; NITRIC OXIDE; PLACEBO; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TAMOXIFEN; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BOLUS INJECTION; BONE METASTASIS; BRAIN METASTASIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DENMARK; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOREGULATION; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LYMPH NODE METASTASIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEPHRECTOMY; OUTPATIENT CARE; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SWEDEN; T LYMPHOCYTE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; TREATMENT OUTCOME;

EID: 39049137115     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Review

References (197)

1. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin., 55: 74-108, 2005.
2. Lindblad, P. Epidemiology of renal cell carcinoma. Scand.J.Surg., 93: 88-96, 2004.
3. Mathew, A., Devesa, S. S., Fraumeni, J. F., Jr., and Chow, W. H. Global increases in kidney cancer incidence, 1973-1992. Eur.J.Cancer Prev., 11: 171-178, 2002.
4. Martel, C. L. and Lara, P. N. Renal cell carcinoma: current status and future directions. Crit Rev.Oncol.Hematol., 45: 177-190, 2003.
5. McLaughlin, J. K. and Lipworth, L. Epidemiologic aspects of renal cell cancer. Semin.Oncol., 27: 115-123, 2000.
6. Storkel, S., Eble, J. N., Adlakha, K., Amin, M., Blute, M. L., Bostwick, D. G., Darson, M., Delahunt. B., and Iczkowski, K. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80: 987-989, 1997.
7. Reuter, V. E. and Presti, J. C., Jr. Contemporary approach to the classification of renal epithelial tumors. Semin.Oncol., 27: 124-137, 2000.
8. Cohen, H. T. and McGovern, F. J. Renal-cell carcinoma. N.Engl.J Med., 353: 2477-2490, 2005.
9. Hemminki. K., Li, X.. and Czene. K. Familial risk of urological cancers: data for clinical counseling. World J.Urol., 21:377-381, 2004.
10. Linehan, W. M., Vasselli, J., Srinivasan, R., Walther, M. M., Merino, M., Choyke, P., Vocke, C., Schmidt, L., Isaacs, J. S., Glenn, G., Toro, J., Zbar, B., Bottaro. D., and Neckers, L. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin.Cancer Res., 10: 6282S-6289S, 2004.
11. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F. M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi. W., Geil, L., and Identification of the von Hippel-Lindau disease tumor suppressor gene. Science, 260: 1317-1320, 1993.
12. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikimets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J., Walther, M. M., Tsui, L. C., Geil, L., Orcutt, M. L., Stackhouse, T., Lipan, J., Slife, L., Brauch. H., Decker, J., Niehans, G., Hughson, M. D., Moch, H., Storkel, S., Lerman, M. I., Linehan, W. M., and Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat.Genet., 16: 68-73, 1997.
13. Tomlinson, I. P., Alam, N. A., Rowan, A. J., Barclay, E., Jaeger, E. E., Kelsell, D., Leigh, I., Gorman, P., Lamlum, H., Rahman, S., Roylance, R. R., Olpin, S., Bevan, S., Barker, K., Hearle, N., Houlston, R. S., Kiuru, M., Lehtonen, R., Karhu, A., Vilkki, S., Laiho, P., Eklund, C., Vierimaa, O., Aittomaki, K., Hietala, M., Sistonen, P., Paetau, A., Salovaara, R., Herva, R., Launonen, V., and Aaltonen, L. A. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat.Genet., 30: 406-410, 2002.
14. Nickerson, M. L., Warren, M. B., Toro, J. R., Matrosova, V, Glenn, G., Turner, M. L., Duray, P., Merino, M., Choyke, P., Pavlovich, C. P., Sharma, N., Walther, M., Munroe, D., Hill, R., Maher, E., Greenberg, C., Lerman, M. I., Linehan, W. M., Zbar, B., and Schmidt, L. S. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell, 2: 157-164, 2002.
15. Atkins, M. B., Avigan, D. E., Bukowski, R. M., Childs, R. W., Dutcher, J. P., Eisen, T. G., Figlin, R. A., Finke, J. H., Flanigan, R. C., George, D. J., Goldberg, S. N., Gordon, M. S., Iliopoulos, O., Kaelin, W. G., Jr., Linehan, W. M., Lipton, A., Motzer, R. J., Novick, A. C., Stadler, W. M., Teh, B. T., Yang, J. C., and King, L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin.Cancer Res., 10: 6277S-6281S, 2004.
16. Kaelin, W. G., Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin.Cancer Res., 10: 6290S-6295S, 2004.
17. Goldstein, N. S. The current state of renal cell carcinoma grading. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80: 977-980, 1997.
18. Fuhrman, S. A., Lasky, L. C., and Limas, C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am.J.Surg.Pathol., 6: 655-663, 1982.
19. Bukowski, R. M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 80: 1198-1220, 1997.
20. Robson, C. J., Churchill, B. M., and Anderson, W. The results of radical nephrectomy for renal cell carcinoma. J. Urol., 101: 297-301, 1969.
21. Guinan, P., Sobin, L. H., Algaba, E, Badellino, F., Kameyama, S., MacLennan, G., and Novick, A. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80: 992-993, 1997.
22. Javidan, J., Stricker, H. J., Tamboli, P., Amin, M. B., Peabody, J. O., Deshpande, A., Menon, M., and Amin, M. B. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J.Urol., 162: 1277-1281, 1999.
23. Haas, G. P., Hillman, G. G., Redman, B. G., and Pontes, J. E. Immunotherapy of renal cell carcinoma. CA Cancer J.Clin., 43: 177-187, 1993.
24. Patel, N. P. and Lavengood, R. W. Renal cell carcinoma: natural history and results of treatment. J.Urol., 119: 722-726, 1978.
25. Elson, P. J., Witte, R. S., and Trump, D. L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res., 48: 7310-7313, 1988.
26. Hoffman, D. M. and Figlin, R. A. Natural history and prognostic factors associated with metastatic renal cell carcinoma. In Renal & adrenal tumors, edited by Arie Belldegrun, 351-358. Oxford university press 2003.
27. Cooney, M. M., Remick, S. C., and Vogelzang, N. J. A medical oncologist's approach to immunotherapy for advanced renal tumors: is nephrectomy indicated? Curr.Urol.Rep., 5: 19-24, 2004.
28. Motzer, R. J.; Bander, N. H., and Nanus, D. M. Renal-cell carcinoma. N.Engl.J Med., 335: 865-875, 1996.
29. Gettman, M. T. and Blute, M. L. Surgical management of renal cell carcinoma invading the vena cava. Curr.Urol.Rep., 3: 37-43, 2002.
30. Alamdari, F. I. and Ljungberg, B. Adrenal metastasis in renal cell carcinoma: A recommendation for adjustment of the TNM staging system. Scand.J.Urol.Nephrol., 39: 277-282, 2005.
31. Canfield, S. E., Kamat, A. M., Sanchez-Ortiz, R. F., Detry, M., Swanson, D. A., and Wood, C. G. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol., 175: 864-869, 2006.
32. Blom, J. H., van Poppel, H., Marechal, J. M., Jacqmin, D., Sylvester, R., Schroder, F. H., and de Prijck, L. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur.Urol., 36: 570-575, 1999.
33. Pantuck, A. J., Zisman, A., Dorey, F., Chao, D. H., Han, K. R., Said, J., Gitlitz, B. J., Figlin, R. A., and Belldegrun, A. S. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J.Urol., 169: 2076-2083, 2003.
34. Larsen, E. H., Frimodt-Møller, P. C., Horn, T., Dorph, S., and von der Maase, H. Nyrecancer. Klaringsrapport nr. 7, 2002. Betænkning fra arbejdsgruppe nedsat af Dansk Urologisk Selskab. www.ugeskriftet.dk, 2002.
35. Novick, A. C. Laparoscopic and partial nephrectomy. Clin.Cancer Res., 10:6322S-6327S, 2004.
36. Hines-Peralta, A. and Goldberg, S. N. Review of radiofrequency ablation for renal cell carcinoma. Clin.Cancer Res., 10: 6328S-6334S, 2004.
37. Werf-Messing, B. Proceedings: Carcinoma of the kidney. Cancer, 32: 1056-1061, 1973.
38. Juusela, H., Malmio, K., Alfthan, O., and Oravisto, K. J. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand.J.Urol.Nephrol., 11: 277-281, 1977.
39. Finney, R. The value of radiotherapy in the treatment of hypernephroma - a clinical trial. Br.J.Urol., 45: 258-269, 1973.
40. Kjaer, M., Frederiksen, P. L., and Engelholm, S. A. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int.J.Radiat.Oncol.Biol. Phys., 13: 665-672, 1987.
41. Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, W., von Wietersheim, J., and Doehn, C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet, 363: 594-599, 2004.
42. Pizzocaro, G., Piva, L., Di Fronzo, G., Giongo, A., Cozzoli, A., Dormia, E., Minervini, S., Zanollo, A., Fontanella, U., Longo, G., and Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J.Urol., 138: 1379-1381, 1987.
43. Pizzocaro, G., Piva, L., Colavita, M., Ferri, S., Artusi, R., Boracchi, P., Parmiani, G., and Marubini, F. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J.Clin.Oncol., 19: 425-431, 2001.
44. Messing, E. M., Manola, J., Wilding, G., Propert, K., Fleischmann, J., Crawford, E. D., Pontes, J. E., Hahn, R., and Trump, D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J.Clin.Oncol., 21: 1214-1222, 2003.
45. Clark, J. I., Atkins, M. B., Urba, W. J., Creech, S., Figlin, R. A., Dutcher, J. P., Flaherty, L., Sosman, J. A., Logan, T. F., White, R., Weiss, G. R., Redman, B. G., Tretter, C. P., McDermott, D., Smith, J. W., Gordon, M. S., and Margolin, K. A. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J.Clin.Oncol., 21: 3133-3140, 2003.
46. Atzpodien, J., Schmitt, E., Gertenbach, U., Fornara, P. Heynemann, H., Maskow, A., Ecke, M., Woltjen, H. H., Jentsch, H., Wieland, W., Wandert, T., and Reitz, M. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br.J.Cancer, 92: 843-846, 2005.
47. Barney, J. and Churchill, E. Adenocarcinoma of the kidney with metastasis to the lung: Cured by nephrectomy and lobectomy. J Urol., 42: 269-276, 1939.
48. Kavolius, J. P., Mastorakos, D. P., Pavlovich, C., Russo, P., Burt, M. E., and Brady, M. S. Resection of metastatic renal cell carcinoma. J.Clin. Oncol., 16: 2261-2266, 1998.
49. Freed, S. Z., Halperin, J. P., and Gordon, M. Idiopathic regression of metastases from renal cell carcinoma. J.Urol., 118: 538-542, 1977.
50. Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., and Bajamonde, A. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N.Engl.J.Med., 338: 1265-1271, 1998.
51. Belldegrun, A., Shvarts, O., and Figlin, R. A. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Cancer J.Sci.Am., 6 Suppl 1: S88-S92, 2000.
52. Rackley, R., Novick, A., Klein, E., Bukowski, R., McLain, D., and Goldfarb, D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J.Urol., 152: 1399-1403, 1994.
53. Bennett, R. T., Lerner, S. E., Taub, H. C., Dutcher, J. P., and Fleischmann, J. Cytoreductive surgery for stage IV renal cell carcinoma. J.Urol., 154: 32-34, 1995.
54. Walther, M. M., Yang, J. C., Pass, H. I., Linehan, W. M., and Rosenberg, S. A. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J.Urol., 158: 1675-1678, 1997.
55. Mickisch, G. H., Garin, A., van Poppel, H., de Prijck, L., and Sylvester, R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358: 966-970, 2001.
56. Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Jr., Munshi, N., and Crawford, E. D. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N.Engl.J.Med., 345: 1655-1659, 2001.
57. Flanigan, R. C., Mickisch, G., Sylvester, R., Tangen, C., van Poppel, H., and Crawford, E. D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J.Urol., 171: 1071-1076, 2004.
58. Flanigan, R. C. Debulking nephrectomy in metastatic renal cancer. Clin.Cancer Res., 10: 6335S-6341S, 2004.
59. Tannock, I. F. Commentary on "cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group Trial 8949". J Clin.Oncol., 18: 39S-42S, 2000.
60. Motzer, R. J. and Russo, P. Systemic therapy for renal cell carcinoma. J.Urol., 163: 408-417, 2000.
61. Yagoda, A., Abi-Rached, B., and Petrylak, D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin.Oncol., 22: 42-60, 1995.
62. Chapman, A. E. and Goldstein, L. J. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma. Semin.Oncol., 22: 17-28, 1995.
63. Amato, R. J. Chemotherapy for renal cell carcinoma. Semin.Oncol., 27: 177-186, 2000.
64. Elhilali, M. M., Gleave, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L., Moore, R., Ernst, S., and Paton, V. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU.Int., 86: 613-618, 2000.
65. Oliver, R. T., Miller, R. M., Mehta, A., and Barnett, M. J. A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol.Biother., 1: 14-20, 1988.
66. Snow, R. M. and Schellhammer, P. F. Spontaneous regression of metastatic renal cell carcinoma. Urology, 20: 177-181, 1982.
67. Vogelzang, N. J., Priest, E. R., and Borden, L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol., 148: 1247-1248, 1992.
68. Finke, J. H., Tubbs, R., Connelly, B., Pontes, E., and Montie, J. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann.N.Y.Acad.Sci., 532: 387-394, 1988.
69. Vogelzang, N. J. and Stadler, W. M. Kidney cancer. Lancet, 352: 1691-1696, 1998.
70. Pfeffer, L. M., Dinarello, C. A., Herberman, R. B., Williams, B. R., Borden, E. C., Bordens, R., Walter, M. R., Nagabhushan, T. L., Trotta, P. P., and Pestka, S. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res., 58: 2489-2499, 1998.
71. Quesada, J. R., Swanson, D. A., Trindade, A., and Gutterman, J. U. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res., 43: 940-947, 1983.
72. Nanus, D. M., Pfeffer, L. M., Bander, N. H., Bahri, S., and Albino, A. P. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res., 50: 4190-4194, 1990.
73. Steineck, G., Strander, H., Carbin, B. E., Borgstrom, E., Wallin, L., Achtnich, U., Arvidsson, A., Soderlund, V., Naslund, I., Esposti, P. L., and Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol., 29: 155-162, 1990.
74. Kriegmair, M., Oberneder, R., and Hofstetter, A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology, 45: 758-762, 1995.
75. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet, 353: 14-17, 1999.
76. Pyrhonen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., and Kellokumpu-Lehtinen, P. L. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J.Clin.Oncol., 17: 2859-2867, 1999.
77. Coppin, C., Porzsolt, F., Awa, A., Kumpf, J., Coldman, A., and Wilt, T. Immunotherapy for advanced renal cell cancer. Cochrane.Database.Syst.Rev., CD001425, 2005.
78. Minasian, L. M., Motzer, R. J., Gluck. L., Mazumdar, M., Vlamis, V., and Krown, S. E. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J.Clin.Oncol., 11: 1368-1375, 1993.
79. Morgan, D. A., Ruscetti, F. W., and Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science, 193: 1007-1008, 1976.
80. Bazan, J. F. Unraveling the structure of IL-2. Science, 257: 410-413, 1992.
81. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature, 411: 380-384, 2001.
82. Schmidinger, M., Hejna, M., and Zielinski, C. C. Aldesteukin in advanced renal cell carcinoma. Expert.Rev.Anticancer Ther., 4: 957-980, 2004.
83. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., and Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N.Engl.J.Med., 313: 1485-1492, 1985.
84. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J.Clin.Oncol., 13: 688-696, 1995.
85. Fisher, R. I., Rosenberg, S. A., and Fyfe, G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J.Sci.Am., 6 Suppl 1: S55-S57, 2000.
86. von der Maase, H., Geertsen, P., Thatcher, N., Jasmin, C., Mercatello, A., Fossa, S. D., Symann, M., Stoter, G., Nagel, G., Israel, L., and Recombinant interleukin-2 in metastatic renal cell carcinoma - a European multicentre phase II study. Eur.J.Cancer, 27: 1583-1589, 1991.
87. Atzpodien, J., Korfer, A., Franks, C. R., Poliwoda, H., and Kirchner, H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet, 335: 1509-1512, 1990.
88. Negrier, S., Escudier, B., Lasset, C., Douillard, J. Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., and Tursz, T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N.Engl.J.Med., 338: 1272-1278, 1998.
89. Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., Liewehr, D. J., Merino, M. J., and Rosenberg, S. A. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J.Clin.Oncol., 21: 3127-3132, 2003.
90. McDermott, D. F., Regan, M. M., Clark, J. L, Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., Tretter, C. P., Urba, W. J., Smith, J. W., Margolin, K. A., Mier, J. W., Gollob, J. A., Dutcher, J. P., and Atkins, M. B. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J.Clin. Oncol., 23: 133-141, 2005.
91. Negrier, S., Maral, J., Drevon, M., Vinke, J., Escudier, B., and Philip, T. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J.Sci.Am., 6 Suppl 1: S93-S98, 2000.
92. Negrier, S., Perol, D and others. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. (ASCO 2005, Late Breaking Abstract 4511).
93. Henriksson, R., Nilsson, S., Colleen, S., Wersall, P., Helsing, M., Zimmerman, R., and Engman, K. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen. Br.J Cancer, 77: 1311-1317, 1998.
94. Bordin, V., Giani, L., Meregalli, S., Bukovec, R., Vaghi, M. M., Mandala, M., Paolorossi, F, Ardizzoia, A., Tancini, G., Barni, S., Frigerio, F., Fumagalli, L., Bordoni, A., Valsuani, G., Di Felice, G., and. Lissoni, P. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol.Int., 64: 3-8, 2000.
95. Atzpodien, J., Hoffmann, R., Franzke, M., Stief, C., Wandert, T., and Reitz, M. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer, 95: 1045-1050, 2002.
96. Geertsen, P. F., Hermann, G. G., von der Maase, H., and Steven, K. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study. J.Clin.Oncol., 10: 753-759, 1992.
97. Law, T. M., Motzer, R. J., Mazumdar, M., Sell, K. W., Walther, P. J., O'Connell, M., Khan, A., Vlamis, V., Vogelzang, N. J., and Bajorin, D. F. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 76: 824-832, 1995.
98. Figlin, R. A., Thompson, J. A., Bukowski, R. M., Vogelzang, N. J., Novick, A. C., Lange, P., Steinberg, G. D., and Belldegrun, A. S. Multi-center, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J.Clin.Oncol., 17: 2521-2529, 1999.
99. Avigan, D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin.Cancer Res., 10: 6347S-6352S, 2004.
100. Bleumer, I., Knuth, A., Oosterwijk, E., Hofmann, R., Varga, Z., Lamers, C., Kruit, W., Melchior, S., Mala, C., Ullrich, S., De Mulder, P., Molders, P. F., and Beck, J. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br.J.Cancer, 90: 985-990, 2004.
101. Escudier, B., Lassau, N., Couanet, D., Angevin, E., Mestati, F., Leborgne. S., Garofano, A., Leboulaire, C., Dupouy, N., and Laplanche, A. Phase II trial of thalidomide in renal-cell carcinoma. Ann.Oncol., 13: 1029-1035, 2002.
102. Motzer, R. J., Berg, W., Ginsberg, M., Russo, P., Vuky, J., Yu, R., Bacik, J., and Mazumdar, M. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J.Clin.Oncol., 20: 302-306, 2002.
103. Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D. L., Cella, D., and Mazumdar, M. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J.Clin.Oncol., 18: 2972-2980, 2000.
104. Aass, N., de Mulder, P. H., Mickisch, G. H., Mulders, P, van Oosterom, A. T., van Poppel, H., Fossa, S. D., de Prijck, L., and Sylvester, R. J. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J.Clin.Oncol., 23: 4172-4178, 2005.
105. Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., Young, N. S., and Barrett, A. J. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N.Engl.J.Med., 343: 750-758, 2000.
106. Takahashi, Y. and Childs, R. W. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma. Clin.Cancer Res., 10: 6353S-6359S, 2004.
107. van Spronsen, D. J., Molders, P. F., and de Mulder, P. H. Novel treatments for metastatic renal cell carcinoma. Crit Rev.Oncol.Hematol., 55: 177-191, 2005.
108. Yang, J. C. Bevacizumab for patients with metastatic renal cancer: an update. Clin.Cancer Res., 10: 6367S-6370S, 2004.
109. Potti, A. and George, D, J. Tyrosine kinase inhibitors in renal cell carcinoma. Clin.Cancer Res., 10: 6371S-6376S, 2004.
110. Gordon, M. S. Novel antiangiogenic therapies for renal cell cancer. Clin.Cancer Res., 10: 6377S-6381S, 2004.
111. Dutcher, J. P. Mammalian target of rapamycin inhibition. Clin.Cancer Res., 10: 6382S-6387S, 2004.
112. Ahmad, T. and Eisen, T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin.Cancer Res., 10: 6388S-6392S, 2004.
113. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, R, Schwartzentruber, D. J.. Topalian, S. L., Steinberg, S. M., Chen, H. X., and Rosenberg, S. A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N.Engl.J.Med., 349: 427-434, 2003.
114. Hainsworth, J. D., Sosman, J. A., Spigel, D. R.. Edwards, D. L., Baughman, C., and Greco, A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin.Oncol., 23: 7889-7896, 2005.
115. Motzer, R. J., Michaelson, M. D., Redman, B. G., Hodes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., Li, J. Z., Bello, C. L., Theuer, C. P., George, D. J., and Rini, B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin.Oncol., 24: 16-24, 2006.
116. Smith, K. A. Interleukin-2: inception, impact, and implications. Science, 240: 1169-1176, 1988.
117. Hokland, M. and Kuppen, P. J. Natural killer cells: from "disturbing" background to central players of immune responses. Mol.Immunol., 42: 381-383, 2005.
118. Farag, S. S. and Caligiuri, M. A. Human natural killer cell development and biology. Blood Rev., 20:123-37, 2006.
119. Mingari, M. C., Gerosa, F., Carra, G., Accolla, R. S., Moretta, A., Zubler, R. H., Waldmann, T. A., and Moretta, L. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature, 312: 641-643, 1984.
120. Espinoza-Delgado, I., Bosco, M. C., Musso, T., Gusella, G. L., Longo, D. L., and Varesio, L. Interleukin-2 and human monocyte activation. J Leukoc.Biol., 57: 13-19, 1995.
121. Ferrante, A. Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors. Immunol.Ser., 57: 417-436, 1992.
122. Fehniger, T. A., Cooper, M. A., and Caligiuri, M. A. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev.. 13: 169-183, 2002.
123. Jeal, W. and Goa, K. L. Aldesleukin (Recombinant Interleukin-2). A review of its Pharmacological Properties, Clinical Efficacy and Tolerability in Patients with Renal Cell Carcinoma. BioDrugs, 7:285-317, 1997.
124. Carlos, T. M. Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukoc.Biol., 70: 171-184, 2001.
125. Sogn, J. A. Tumor immunology: the glass is half full. Immunity, 9: 757-763, 1998.
126. Pardoll, D. Does the immune system see tumors as foreign or self? Annu.Rev.Immunol., 21: 807-839, 2003.
127. van der, B. P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den, E. B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254: 1643-1647, 1991.
128. Rosenberg, S. A. Shedding light on immunotherapy for cancer. N.Engl.J Med., 350: 1461-1463, 2004.
129. Michael, A. and Pandha, H. S. Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol., 4: 215-223, 2003.
130. Novellino, L., Castelli, C., and Parmiani, G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol.Immunother., 54: 187-207, 2005.
131. Schmidt, S. M., Schag, K., Muller, M. R., Weinschenk, T., Appel, S., Schoor, O., Weck, M. M., Grunebach, F., Kanz, L., Stevanovic, S., Rammensee, H. G., and Brossart, P. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res., 64: 1164-1170, 2004.
132. Hanada, K., Yewdell, J. W., and Yang, J. C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature, 427: 252-256, 2004.
133. Vissers, J. L., De Vries, I. J., Schreurs, M. W., Engelen, L. P., Oosterwijk, E., Figdor, C. G., and Adema, G. J. The renal cell carcinoma-associated antigem G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res., 59: 5554-5559, 1999.
134. Ronsin, C., Chung-Scott, V., Poullion, I., Aknouche, N., Gaudin, C., and Triebel, F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol., 163: 483-490, 1999.
135. Probst-Kepper, M., Stroobant, V., Kridel. R., Gaugler, B., Landry, C., Brasseur, F., Cosyns, J. P., Weynand, B., Boon, T., and Van Den Eynde, B. J. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J Exp.Med., 193: 1189-1198, 2001.
136. Neumann, E., Engelsberg, A., Decker, J., Storkel, S., Jaeger, E., Huber, C., and Seliger, B. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. 58: 4090-4095, 1998.
137. Bui, M. H., Seligson, D., Han, K. R., Pantuck, A. J., Dorey, F. J., Huang, Y., Horvath, S., Leibovich, B. C., Chopra, S., Liao, S. Y., Stanbridge, E., Lerman, M. I., Palotie, A., Figlin, R. A., and Belldegrun, A. S. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin.Cancer Res., 9: 802-811, 2003.
138. Atkins, M., Regan, M., McDermott, D., Mier, J., Stanbridge, E., Youmans, A., Febbo, P., Upton, M., Lechpammer, M., and Signoretti, S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin.Cancer Res., 11: 3714-3721, 2005.
139. Foss, F. M. Immunologic mechanisms of antitumor activity. Semin.Oncol., 29: 5-11, 2002.
140. Britten, C. M., Gouttefangeas, C., and Kreiter, S. Cancer immunotherapy 2005: Mainz, Germany, 12-13 May 2005. Cancer Immunol.Immunother., 55: 475-480, 2006.
141. Malmberg, K. J. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol. Immunother., 53: 879-892, 2004.
142. Malmberg, K. J. and Ljunggren, H. G. Escape from immune- and non-immune-mediated tumor surveillance. Semin.Cancer Biol., 2005.
143. Takahashi, A., Hanson, M. G., Norell, H. R., Havelka, A. M., Kono, K., Malmberg, K. J., and Kiessling, R. V. Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress. J.Immunol., 174: 6080-6087, 2005.
144. O'Byrne, K. J. and Dalgleish, A. G. Chronic immune activation and inflammation as the cause of malignancy. Br.J.Cancer, 85: 473-483, 2001.
145. Coussens, L. M. and Werb, Z. Inflammation and cancer. Nature, 420: 860-867, 2002.
146. Seaman, W. E., Gindhart, T. D., Blackman, M. A., Dalal, B., Talal, N., and Werb, Z. Suppression of natural killing in vitro by monocytes and polymorphonuclear leukocytes: requirement for reactive metabolites of oxygen. J.Clin.Invest, 69: 876-888, 1982.
147. Hansson, M., Asea, A., Ersson, U., Hermodsson, S., and Hellstrand, K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J.Immunol., 156: 42-47, 1996.
148. Hellstrand, K., Asea, A., Dahlgren, C., and Hermodsson, S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J.Immunol., 153: 4940-4947, 1994.
149. Malmberg, K. J., Arulampalam, V., Ichihara, F., Petersson, M., Sold, K., Andersson, T., Lenkei, R., Masucci, G., Pettersson, S., and Kiessling,
150. Kono, K., Salazar-Onfray, F., Petersson, M., Hansson, J., Masucci, G., Wasserman, K., Nakazawa, T., Anderson, P., and Kiessling, R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur.J.Immunol., 26: 1308-1313, 1996.
151. Tartour, F., Latour, S., Mathiot, C., Thiounn, N., Mosseri, V., Joyeux, I., D'Enghien, C. D., Lee, R., Debre, B., and Fridman, W. H. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int.J.Cancer, 63: 205-212, 1995.
152. Finke, J. H., Zea, A. H., Stanley, J., Longo, D. L., Mizoguchi, H., Tubbs, R. R., Wiltrout, R. H., O'Shea, J. J., Kudoh, S., and Klein, E. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 53: 5613-5616, 1993.
153. Hellstrand, K. and Hermodsson, S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int.Arch.Allergy Appl.Immunol., 92: 379-389, 1990.
154. Hellstrand, K. Histamine in cancer immunotherapy: a preclinical background. Semin.Oncol, 29: 35-40, 2002.
155. Hellstrand, K. and Hermodsson, S. Histamine H2-receptor-mediated regulation of human natural killer cell activity. J.Immunol., 137: 656-660, 1986.
156. Betten, A., Dahlgren, C., Hermodsson, S., and Hellstrand, K. Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met. Scand.J.Immunol., 58: 321-326, 2003.
157. Hellstrand, K., Asea, A., and Hermodsson, S. Role of histamine in natural killer cell-mediated resistance against tumor cells. J.Immunol., 145: 4365-4370, 1990.
158. Asea, A., Hermodsson, S., and Hellstrand, K. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand.J.Immunol., 43:9-15, 1996.
159. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
160. Jennings, P. E., Donald, J. J., Coral, A., Rode, J., and Lees, W. R. Ultrasound-guided core biopsy. Lancet, 1: 1369-1371, 1989.
161. Shi, S. R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem.Cytochem., 39: 741-748, 1991.
162. Miller, R. T., Swanson, P. E., and Wick, M. R. Fixation and epitope retrieval in diagnostic immunohistochemistry: a concise review with practical considerations. Appl.Immunohistochem.Mol.Morphol., 8: 228-235, 2000.
163. Sabattini, E., Bisgaard, K., Ascani, S., Poggi, S., Piccioli, M., Ceccarelli, C., Pieri, F., Fraternali-Orcioni, G., and Pileri, S. A. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP. ChemMate, CSA, LABC, and SABC techniques. J Clin.Pathol., 51: 506-511, 1998.
164. Gunderson, H. J., Bendtsen, T. F., Korbo, L., Marcussen, N., Moller, A., Nielsen, K., Nyengaard, J. R., Pakkenberg, B., Sorensen, F. B., and Vesterby, A. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS, 96: 379-394, 1988.
165. Tandrup, T. Unbiased estimates of number and size of rat dorsal root ganglion cells in studies of structure and cell survival. J Neurocytol., 33: 173-192, 2004.
166. Gunderson, H. J. and Jensen, E. B. The efficiency of systematic sampling in stereology and its prediction. J Microsc., 147 (Pt 3): 229-263, 1987.
167. Gundersen, H. J. Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc., 143 (Pt 1): 3-45, 1986.
168. Petersen, M. S., Petersen, C. C., Agger, R., Hokland, M., and Gunderson, H. J. A simple method for unbiased quantitation of adoptively transferred cells in solid tissues. J Immunol.Methods, 309:173-81, 2006.
169. Hakansson, A., Gustafsson, B., Krysander, L., and Hakansson, L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res., 18: 33-39, 1998.
170. Hansen, S., Grabau, D. A., Rose, C.. Bak, M., and Sorensen, F. B. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest, 78: 1563-1573, 1998.
171. Jensen, V., Sorensen, F. B., Bentzen, S. M., Ladekarl, M., Nielsen, O. S., Keller, J., and Jensen, O. M. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology. 32: 536-546, 1998.
172. Wallace, D., Hildesheim, A., and Pinto, L. A. Comparison of benchtop microplate beta counters with the traditional gamma counting method for measurement of chromium-51 release in cytotoxic assays. Clin.Diagn. Lab Immunol., 11: 255-260, 2004.
173. Hokland, P, Bonde, J and others. Isolation of Mononuclear cells from Human Blood and Bone Marrow and Identifications of Leukocytes Subsets by Multiparameter flow Cytometry. Cell Biology (Edited by Celis, JE), 164-169.
174. Rosenberg, S. A., Yang, J. C., and Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat.Med., 10: 909-915, 2004.
175. Bukowski, R. M., Olencki, T., Wang, Q., Peereboom, D., Budd, G. T., Elson, P., Sandstrom, K., Tuason, L., Rayman, P., Tubbs, R., McLain, D., Klein, E., Novick, A., and Finke, J. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. J.Immunother., 20: 301-311, 1997.
176. Cohen, P. J., Lotze, M. T., Roberts, J. R., Rosenberg, S. A., and Jaffe, E. S. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am.J.Pathol., 129: 208-216, 1987.
177. Rubin, J. T., Elwood, L. J., Rosenberg, S. A., and Lotze, M. T. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res., 49: 7086-7092, 1989.
178. Hernberg, M. Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Med.Oncol., 16: 145-153, 1999.
179. Fumagalli, L. A., Vinke, J., Hoff, W., Ypma, E., Brivio, F., and Nespoli, A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother., 26: 394-402, 2003.
180. Hakansson, A., Gustafsson, B., Krysander, L., and Hakansson, L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br.J.Cancer, 74:670-676, 1996.
181. Hakansson, A., Gustafsson, B., Krysander, L., Hjelmqvist, B., Rettrup, B., and Hakansson, L. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. BrJ.Cancer, 85: 1871-1877, 2001.
182. Sato, M., Radoja, S., Marino, M., and Frey, A. B. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J.Immunol., 167:5583-5593, 2001.
183. Hansson, M., Hermodsson, S., Brune, M., Mellqvist, U. H., Naredi, P., Betten, A., Gehlsen, K. R., and Hellstrand, K. Histamine protects T cells and natural killer cells against oxidative stress. J.Interferon Cytokine Res., 19: 1135-1144, 1999.
184. Hansson, M., Asea, A., Hermodsson, S., and Hellstrand, K. Histaminergic regulation of NK-cells: protection against monocyte- induced apoptosis. Scand.J.Immunol., 44: 193-196, 1996.
185. Hellstrand, K., Asea, A., and Hermodsson, S. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. J.Leukoc.Biol., 55: 392-397, 1994.
186. Hellstrand, K. and Hermodsson, S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand.J.Immunol., 34: 741-752, 1991.
187. Brune, M. and Hellstrand, K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br.J.Haematol., 92: 620-626, 1996.
188. Lurie, Y., Nevens, F., Aprosina, Z. G., Fedorova, T. A., Kalinin, A. V, Klimova, E. A., Ilan, Y., Maevskaya, M. V., Warnes, T. W., Yuschuk, N. D., Hellstrand, K., and Gehlsen, K. R. A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. J.Viral Hepat., 9: 346-353, 2002.
189. Mellqvist, U. H., Wallhult, E and others. Histamine dihydrochloride, interleukin-2 and interferon-alfa in multiple myeloma. Int.J.Immunother. 15, 125-130. 1999.
190. Schmidt, H., Larsen, S., Bastholt, L., Fode, K., Rytter, C., and von der Maase, H. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Ann.Oncol., 13:1919-1924, 2002.
191. Agarwala, S. S., Glaspy, J., O'Day, S. J., Mitchell, M., Gutheil, J., Whitman, E., Gonzalez, R., Hersh, E., Feun, L., Belt, R., Meyskens, F., Hellstrand, K., Wood, D., Kirkwood, J. M., Gehlsen, K. R., and Naredi, P. Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interieukin-2 Alone in Patients With Metastatic Melanoma. J.Clin.Oncol., 20: 125-133, 2002.
192. Agarwala, S. S., Hellstrand, K., Gehlsen, K., and Naredi, P. Immuno-therapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunol.Immunother., 53: 840-841, 2004.
193. Donskov, F., von der Maase, H., Henriksson, R., Stierner, U., Wersall, P., Nellemann, H., Hellstrand, K., Engman, K., and Naredi, P. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. Ann Oncol, 13: 441-449, 2002.
194. Hellstrand, K., Hansson, M., and Hermodsson, S. Adjuvant histamine in cancer immunotherapy. Semin.Cancer Biol., 10: 29-39, 2000.
195. Hellstrand, K., Brune, M., Naredi, P., Mellqvist, U. H., Hansson, M., Gehlsen, K. R., and Hermodsson, S. Histamine: a novel approach to cancer Immunotherapy. Cancer Invest, 18: 347-355, 2000.
196. Hellstrand, K., Brune, M., Dahlgren, C., Hansson, M., Hermodsson, S., Lindner, P., Mellqvist, U. H., and Naredi, P. Alleviating oxidative stress in cancer immunotherapy: a role for histamine? Med.Oncol., 17: 258-269, 2000.
197. Bukowski, R. M., Negrier, S., and Elson, P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin.Cancer Res., 10: 6310S-6314S, 2004.